19th Annual Non-Dilutive Funding Summit

The 19th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including ARPA-H, SEED, NINDS, NHLBI, NIMHD, NCI and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.

Additionally, the 2023 FreeMind Elite honorees from AmplifiDx, Sapience Therapeutics, Marker Therapeutics, and Vincere Biosciences took to the stage to present about their compies research and pipelines.

This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences. The 20th Non-Dilutive Funding Summit will be January 8, 2025.

“Project Accelerator Transition Innovation Office”

Advanced Research Project Agency for Health (ARPA-H)

Some breakthrough ideas don’t get enough attention because they’re too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. ARPA-H aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will have only extramural labs, and it will facilitate research directed at solving practical problems. ARPA-H is designed to be the DARPA of human health.

ARPA-H advances high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity. With a scope spanning the molecular to the societal, ARPA-H programs have the potential to radically improve human health.

Craig Gravitz

Director, PATIO

Craig Gravitz is designing and implementing the transition and commercial strategy for the Advanced Research Projects Agency for Health (ARPA-H). Prior to joining ARPA-H, Mr. Gravitz launched and ran a research and development program at the Defense Logistics Agency. That program was inspired by DARPA, but also by private sector innovation models like design thinking and lean start up. Using those models, he developed an effective framework to translate work into real world environments: real people used those innovations. He is a licensed attorney and has previously serviced as a contracting officer.

Jenica Patterson

Director of the Trechnology Transfer and Transition (T3X) Division, PATIO

Jenica Patterson, Ph.D. is the Director of the Technology Transfer and Transition (T3X) Division within the Project Accelerator Transition Innovation Office (PATIO), where she oversees public-private partnerships for transition, the FDA engagement strategy, and the small business program for ARPA-H.

Dr. Patterson received her Ph.D. in Neuroscience at the University of Maryland, Baltimore County (UMBC), and post-doc at the intramural NIH Program. She served as a Science and Technical Advisor from 2014-2018 at the Defense Advanced Research Project Agency (DARPA) in the Biological Technologies Office (BTO) and Information Innovation Office (I2O), supporting neurotechnology, OMICs and gene editing programs.  Further she served as a Program Director at NIH from 2018-2023 on various translational therapeutic and diagnostic programs at the National Institutes of Alcohol Abuse and Alcoholism (NIAAA) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) on the Rapid Acceleration of Diagnostic (RADx) program.